

Federal Circuit Affirms Axinn's Trial Victory for Alvogen

NEWS | 1 MIN READ

December 27, 2019

In Axinn's latest victory for its client Alvogen, the United States Court of Appeals for the Federal Circuit affirmed a district court decision invalidating patents asserted against Alvogen under the Hatch-Waxman Act. After a bench trial in 2018, the United States District Court for the District of Delaware granted judgment to Alvogen Malta Operations, Ltd. ("Alvogen") over patents related to Persion Pharmaceuticals LLC's ("Persion") hydrocodone extended-release capsules, Zohydro[®]. Persion sued Alvogen for patent infringement over two patents claiming methods of treating patients that have mild or moderate hepatic impairment with an extended-release hydrocodone dosage form.

Axinn was the lead trial counsel, and the district court ruled that the patent claims asserted by Persion were invalid as obvious under 35 U.S.C. § 103, and for failure to satisfy the written description requirement of 35 U.S.C. § 112(a). The decision removed Persion's patents as a barrier to Alvogen bringing its lower-cost generic product to market more than a decade before the patents were set to expire. Persion appealed and, on December 27, 2019, the Federal Circuit ruled in Alvogen's favor on obviousness without reaching the written description issue. The Axinn team included Matt Becker, Ted Mathias, and Thomas Hedemann.

Related People

Matthew J. Becker
Ted Mathias
Thomas K. Hedemann

Related Services

Intellectual Property

Related Locations

Hartford
Washington, DC

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST

- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved